Latest news with #EuronextParis
Business Wire
14 hours ago
- Business
- Business Wire
Innate Pharma Announces Its Participation in the BTIG Virtual Biotechnology Conference
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') today announced that the company's CEO Jonathan Dickinson and COO Yannis Morel will participate in the BTIG Virtual Biotechnology Conference being held on July 29-30, 2025. BTIG, a global financial services firm specializing in investment banking, institutional trading, research and related brokerage services, recently initiated analyst coverage of Innate Pharma. The Fireside chat will be held on Wednesday July 30 at 2pm EST, with 1x1 meetings hosted the same day. About BTIG BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 700 employees, BTIG, LLC and its affiliates operate out of 20 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (A ntibody-based NK cell E ngager T herapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at and follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Business Wire
6 days ago
- Business
- Business Wire
SFL Releases Its 2025 Interim Financial Report
PARIS--(BUSINESS WIRE)--Regulatory News: SFL (Paris:FLY) has published its Interim Financial Report for the six months ended 30 June 2025 and filed it with France's securities regulator, Autorité des Marchés Financiers (AMF). The document can be viewed at the SFL website, in the 'Publications' section under "Results". About SFL Referent in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.7 billion and is focused on the Central Business District of Paris (# Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies. As France's oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties. With its sights firmly set on the future, SFL is committed to sustainable real estate with the aim of building the city of tomorrow and helping to reduce carbon emissions in its sector. Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA S&P rating: BBB+ stable outlook
Yahoo
17-07-2025
- Business
- Yahoo
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders NANTES, France, July 17, 2025, 6:30pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs, today launched the inaugural edition of its Newsletter, designed specifically for individual shareholders and investors in France and internationally. " This year, OSE Immunotherapeutics celebrates the 10th anniversary of its listing on Euronext Paris and we are delighted to introduce this new communication channel for our valued individual shareholders" said Fiona Olivier, Chief Corporate Affairs & Investor Relations Officer of OSE Immunotherapeutics. " Beyond providing updates on Company developments, the Newsletter gives us an opportunity to shine a spotlight on our teams and offer deeper insights into topics that are typically only touched on in press releases. It's also a way for us to express our appreciation for the continued trust and support of our investor community. " Published regularly in French and English, the Newsletter will be available in the 'Investors' section of the OSE Immunotherapeutics website. To subscribe to receive our Newsletters: ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Click and follow us on LinkedIn. Follow us on Fiona Dé France Contact Media: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Contact Media:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statements This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250717_Newsletter_vfSign in to access your portfolio
Business Insider
16-07-2025
- Automotive
- Business Insider
Renault shares crash 17% after the automaker's profit warning
Renault shares crashed as much as 17% after the French automaker cut its guidance for the year. Late Tuesday, the company lowered its operating margin guidance for 2025 from at least 7% to 6.5%. On Wednesday, Renault's stock on the Euronext Paris exchange was down 16.3% at 34.79 euros at 10:00 a.m. local time, marking its steepest one-day drop since the start of the COVID-19 pandemic in 2020. Renault attributed the revised forecast to "the deterioration of the automotive market trends with an increasing commercial pressure" from competitors and a slowdown in the retail segment. The company is also aiming for a free cash flow between 1 billion to 1.5 billion euros, down from at least 2 billion euros previously. Separately, Renault announced the appointment of Duncan Minto as interim CEO, following the resignation of Luca de Meo last month. De Meo joined luxury group Kering. Renault is expected to report half-year earnings on July 31. The company's shares are down more than 25% this year.
Business Insider
16-07-2025
- Automotive
- Business Insider
Renault shares crash 17% after automaker cuts guidance
Renault shares crashed as much as 17% after the French automaker cut its guidance for the year. Late Tuesday, the company lowered its operating margin guidance for 2025 from at least 7% to 6.5%. On Wednesday, Renault's stock on the Euronext Paris exchange was down 16.3% at 34.79 euros at 10:00 a.m. local time, marking its steepest one-day drop since the start of the COVID-19 pandemic in 2020. Renault attributed the revised forecast to "the deterioration of the automotive market trends with an increasing commercial pressure" from competitors and a slowdown in the retail segment. The company is also aiming for a free cash flow between 1 billion to 1.5 billion euros, down from at least 2 billion euros previously. Separately, Renault announced the appointment of Duncan Minto as interim CEO, following the resignation of Luca de Meo last month. De Meo joined luxury group Kering. Renault is expected to report half-year earnings on July 31. The company's shares are down more than 25% this year.
